CRF Design for Oncology vs Cardiology Trials: Key Differences and Best Practices

Published on 22/12/2025

Optimizing CRF Design for Oncology and Cardiology Clinical Trials

Clinical trials across therapeutic areas require tailored Case Report Forms (CRFs) that align with the study objectives and disease-specific endpoints. Designing CRFs for oncology and cardiology trials presents unique challenges and considerations due to the complexity, duration, and regulatory focus in each area. This tutorial explores how to customize CRFs for these two major therapeutic areas, offering best practices for clinical data professionals, trial designers, and regulatory specialists.

Table of Contents

Why Therapeutic-Specific CRF Design Matters:

A standardized CRF cannot meet the nuanced requirements of every clinical indication. Oncology trials involve detailed tumor assessments, biomarker data, and adverse event tracking, while cardiology studies often focus on ECGs, biomarkers like troponin, and cardiovascular event adjudication. Tailoring the CRF helps to:

Ensure complete and relevant data capture
Improve protocol compliance and patient safety
Enhance data quality and submission readiness
Streamline Source Data Verification (SDV)

Overview of Oncology CRF Design Characteristics:

Oncology CRFs are typically extensive due to the complexity of cancer trials and long-term follow-up. Key design elements include:

Tumor Assessment Modules: Including RECIST measurements, imaging data, and progression status
Biomarker and Genetic Testing: Capturing detailed molecular pathology results
Treatment Cycle Tracking: Documenting each chemotherapy

or immunotherapy cycle

Adverse Event Management: Recording severity and causality, often using CTCAE criteria

Survival Data Collection: Time-to-event outcomes like PFS (Progression-Free Survival) and OS (Overall Survival)

Key Features of Cardiology CRF Design:

Cardiology trials often involve acute and chronic assessments, requiring precision and consistency. Key features include:

Vital Sign and ECG Tracking: Including QTc intervals and rhythm analysis
Cardiac Biomarkers: Fields for troponin, BNP, cholesterol levels
Adverse Event Recording: Including heart attacks, arrhythmias, and stent thrombosis
Device Implantation Details: For pacemakers or cardiac stents
Medication Modules: Longitudinal tracking of anticoagulants, beta-blockers, and other cardiac drugs

Comparative Table: Oncology vs Cardiology CRF Modules

Component	Oncology Trials	Cardiology Trials
Imaging Data	RECIST, MRI, PET-CT	Angiography, Echocardiogram
Lab Data	Biomarkers, Hematology	Cardiac Enzymes, Lipids
Adverse Events	CTCAE-based	MedDRA Cardiovascular
Study Duration	Often multi-year	6–12 months typical
Treatment Tracking	Cycles, dosing regimens	Device use, medication timing

Best Practices for Therapeutic-Specific CRF Customization:

1. Align with Protocol Objectives

CRFs should reflect protocol endpoints, whether tumor response or MACE (Major Adverse Cardiovascular Events). Early collaboration between clinical and data teams ensures alignment.

2. Use Modular Design Approach

Create reusable CRF modules for general data (e.g., demographics, vitals) and develop indication-specific modules for oncology or cardiology needs.

3. Implement Smart Edit Checks

Use dynamic edit checks within Electronic Data Capture (EDC) systems that trigger based on therapeutic context. For example, if “cancer type” is filled as “breast,” display HER2/ER/PR marker fields.

4. Reference Data Standards

Follow CDISC SDTM and ADaM guidelines. Oncology trials may utilize GMP quality control linked forms, while cardiology may emphasize lab standardization.

Common Pitfalls in Therapeutic CRF Design:

Using generic CRFs that miss disease-specific data
Collecting data not required for analysis or submission
Overloading sites with complex forms
Not adapting CRF logic to specific trial arms
Failure to consult regulatory guidance such as EMA expectations

Case Example: Oncology Phase III Trial

An oncology study evaluating immunotherapy in NSCLC required complex CRF modules capturing PD-L1 expression, tumor mutation burden (TMB), and immune-related AE tracking. The CRF used multiple visit-based modules, integrated image upload fields, and safety reporting workflows.

Case Example: Cardiology Device Study

A cardiology study for a new stent device focused on short-term outcomes and device performance. The CRF design emphasized real-time ECG data entry, procedural details, and stent placement logs. User-friendly interface improved site compliance significantly.

Validation, Testing, and CRF Maintenance:

CRFs must undergo testing across different indication arms, especially in multi-therapeutic trials. Ensure integration with equipment qualification where medical devices are involved, and document CRF change logs and completion guides for each therapeutic area.

Training and Documentation:

Site staff must receive CRF-specific training that reflects the complexity of the indication. Oncology trials may need specialized AE grading instructions, while cardiology studies often require ECG interpretation training. Use resources like SOP training pharma for structured learning content.

Improving CRF Outcomes with Domain Expertise:

Involving clinical specialists in form reviews ensures accuracy and relevance. Additionally, referencing Stability Studies principles when designing long-term oncology CRFs can ensure robust follow-up module design for post-treatment surveillance.

Conclusion: Strategic CRF Design Enhances Study Success

Oncology and cardiology trials demand thoughtful CRF customization to meet clinical, regulatory, and operational expectations. By implementing disease-specific modules, applying smart validation logic, and ensuring proper training, CRF design can directly impact data quality and trial outcomes. Whether addressing tumor progression or cardiac endpoints, the CRF is the foundation of meaningful clinical data capture.